RT @RHEUMarampa: SURPASS was a head-to-head study comparing SEC vs ADA biosimilar (SDZ-ADL) in r-axSpA on spinal radio p
Tweet Content
SURPASS was a head-to-head study comparing SEC vs ADA biosimilar (SDZ-ADL) in r-axSpA on spinal radio progression:
Results showed no significant diff in spinal radio progression bet. the 2 grps.
Biosimilars remain tx options for r-axSpA.
#ACR22 @RheumNow ABST#L15
Show on Archive Page
On
Display in Search Results
On
PDQ
Off